Next Phase Newsletter

A venture capital firm founded in 2016 with a primary office in the US will soon be investing from a third fund, dedicated towards seed-stage companies that solve the most critical problems of today. The typical check size is around $1M USD and the firm expects to invest in 4-6 companies in the next year. The firm invests globally with a focus on North America.

The firm is mainly focused on deep tech opportunities related to prevalent industrial, agriculture, climate, and healthcare issues. Within healthcare, the firm is primarily interested in scalable technologies that assist the aging population and chronic diseases and address rising healthcare costs. The firm is open to all modalities within the diagnostics, medical devices, and biomanufacturing spaces, but does not invest in therapeutics. Though opportunistic, the firm looks for technology in development phases that can seamlessly be integrated into workflows and meet the existing market demand. The firm is open to all indications related to the aging population and chronic disease, including renal health, heart disease, and oncology.

The firm is looking for coachable, open-minded, and growth-centered management teams. The firm will typically lead and require board seat to work closely with companies. However, co-leading and syndicate investments are also feasible.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Founded in 2019, a China-based firm sponsored by the local municipal government focuses on investment, BD and other forms of collaboration with disruptive medical technologies. With in-depth experience from their teams covering R&D, registration, distribution and sales in China and around the world, the group is looking for domestic and cross-border partnerships in terms of investment, license-in, joint venture, distribution and others.

The firm focuses on Class II and Class III medical devices from in-development to commercialization stage, especially prototype-ready projects. The firm pays special attention to companies that are developing projects related to neuro-surgery, endoscope and minimally invasive devices, stroke, cardiovascular disease, eye disease, medical robots, etc.

The firm prefers companies with a Chinese angle and are open to discussing China rights.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm was founded in 1997 and operates offices in Berlin, Munich, Istanbul, and London. With EUR 2 billion under management across all fund streams, 9 IPOs, and 31 trade sales, the firm is one of Europe’s most established and active venture capital firms. Its dedicated Health Fund leads or co-leads investments, typically with an initial investment of €4-6 million and an average of €6-12 million per company over the lifetime of the investment. The geographical focus is on companies across Europe and selectively in the US and Israel.

The firm focuses on technologies across healthcare sectors, including digital health, diagnostics, medical devices, R&D tools and biopharma, with the ultimate goal of delivering strong, positive patient outcomes.

The firm is open to investing in companies at early stages with proof-of-concept, clinically relevant data and/or strong IP positions.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A life sciences venture capital fund founded in 2014 with an office in Central, Hong Kong currently manages three funds with ~ $600 million assets under management, and is actively seeking investment opportunities. On average, the size of investment is $5-25M in venture rounds. The firm prefers to act as the lead investor but is also open to co-investing. The firm looks for companies located around the globe, with a preference in the US and China. The firm is actively seeking new investment opportunities.

The firm is focused on Therapeutics and Medical Devices opportunities. The core focused therapeutic areas include oncology, immunology, metabolic and CNS diseases, but the firm is also focused on new modalities and platform technologies. The firm is also interested in interventional, novel medical devices in cardiovascular, neuro-vascular & lung diseases.

The firm prefers a management team with strong scientific background and expertise, successful track records would be a plus but is not required. The firm generally takes a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm was founded in 2022 and based in New York, New York. Fund I of $100M USD, dedicated towards opportunities starting at Series A rounds. The typical investment size ranges from 5mm – 10mm and the firm expects to invest in 2-3 companies in the next year. The firm focuses on opportunities in the United States and territories. The firm invests in innovative healthcare companies that demonstrate the potential to increase accessibility, improve outcomes, and reduce costs, ultimately contributing to the advancement of sustainable and equitable healthcare solutions.

The firm focuses on unmet needs and underserved communities. The firm primarily looks at services, digital health, medical devices, all through a policy lens, and does not consider pharmaceuticals. Within medical devices, the firm is interested in software enabled devices in development phases. The firm is opportunistic within the digital health sector. While the firm is open to all indications, areas with unmet needs (women’s health) are of interest.

The firm does not have any requirements of the management team. The firm will both lead and co-lead investments and require board seating.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

An early-stage private investment firm is based in Silicon Valley, CA. The initial investments are typically $25,000-$100,000 and the firm can scale investments from there. The firm also provides select startups with business development support through a no-fee program. The firm will consider investing in companies worldwide.

The firm is interested in investing in digital health and medical technology and invests in subsectors in which the firm and its industry partners can apply expertise; within medical devices, typically this means products that have a significant software component, including biosensors, wearables, and health monitoring devices. Within digital health, the firm’s  interests include: Care Management, Hospital Workflow, Diagnostics, A.I. & Big Data, Population Health, and Patient Adherence. The firm prefers B2B business models.

The firm prefers to invest in companies with at least two co-founders, one with technical expertise and one with business expertise. In addition to due diligence on the management team and technology, the firm also considers a product’s potential market opportunity.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm in Japan invests in life science, biotech, IT and software, and agriculture. Currently, the firm manages two funds: one fund which funds later stage companies, and another fund which is an open innovation fund to support the creation of companies and early-stage startups. The firm will also support company creation and sales in Japan as well as overseas. In total, the firm has about $400M to invest from, with $5M-10M as a typical check size per round and the same amount reserved for future follow-on investments. The firm is open to investing in all financial rounds and all sectors of life science and biotech. The firm invests globally.

The firm invests in all sectors of life science and biotech including, but not limited to, therapeutics, diagnostics, medical devices, digital health, etc. across all stages of development, focusing on early stage. Within therapeutics, the firm is open to investing in all modalities including novel biologics (i.e. cell & gene therapy). The firm is also open to all indications including orphan diseases.

The firm does not have specific management team requirements, however the firm will take a board or observer seat. The firm is open to acting as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.